Therapeutic Response

PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Cisplatin in combination with Fluorouracil and Pembrolizumab in patients with Esophageal Adenocarcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10. This indication is based on KEYNOTE-590, randomised, double-blind, placebo-controlled trial of 749 patients in which cisplatin and fluorouracil was evaluated with and without pembrolizumab.
Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg) in combination with platinum and flouropyrimidine-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.